Source link : https://www.newshealth.biz/health-news/ema-refuses-marketing-authorization-for-alzheimers-drug/
In its July 2024 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended not granting marketing authorization for Leqembi (lecanemab; Eisai GmbH), a medicine for the treatment of Alzheimer’s disease. The committee considered that the observed effect of Leqembi on delaying cognitive decline did not counterbalance the […]
Author : News Health
Publish date : 2024-07-26 14:28:01
Copyright for syndicated content belongs to the linked Source.
Categories